OVARIAN
BGOG-ov-1
A Phase II international multicenter randomized study testing the effect on survival of prolonging platinum-free interval in patients with ovarian cancer recurring between 6 and 12 months after previous platinum based chemotherapy.
Learn More ->
BGOG-ov-2
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Learn More ->
BGOG-ov-3
A Multicentre, Randomized, Double-Blind, Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination with Standard Treatment of Carboplatin and Paclitaxel Compared to Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer.
Learn More ->
BGOG-ov-4
Phase III Randomised Study of Bevacizumab plus Chemotherapy versus Chemotherapy alone in Patients with Platinum Resistant Ovariumcancer.
Learn More ->
BGOG-ov-5
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.
Learn More ->
BGOG-ov-6
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Learn More ->
BGOG-ov-7
Randomized Phase III trial of Paclitaxel-Carboplatin with or without concomittant and maintenance AMG386 as First-line therapy of Stage III-IV ovarian, fallopian tube and peritoneal carcinoma.
Learn More ->
BGOG-ov-8
Phase III, multicenter, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.
Learn More ->
BGOG-ov-9
A Randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer.
Learn More ->
BGOG-ov-11
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum.
Learn More ->
BGOG-ov-13
A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapsed ovarian sex-cord stromal tumours.
Learn More ->
BGOG-ov-14
A Phase 3 Randomized Double-blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer.
Learn More ->
BGOG-ov-15
A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy
Learn More ->
BGOG-ov-16
A non-interventional Belgian study to collect data on the safety and efficacy of frontline Bevacizumab treatment in ovarian cancer patients ≥70 years.
Learn More ->
BGOG-ov-17
A multicenter Phase III randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/Chemotherapy first line.
Learn More ->
BGOG-ov-18
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.
Learn More ->
BGOG-ov-19
Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
Learn More ->
BGOG-ov-26
Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Niraparib Versus Placebo in women who have not progressed after first line chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Learn More ->
ENDOMETRIUM
BGOG-en-1
A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer.
Learn More ->
CERVIX
BGOG-cx-9
An Open-Label, Randomized, Phase 3 Clinical Trial of the checkpoint inhibitor REGN2810 versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or metastatic Platinum-Refractory Cervical Carcinoma
Sponsor: Regeneron Pharmaceuticals, Inc
Participating sites:
- CHU UCL Namur, site Sainte Elisabeth, Namur
- UZ Leuven, Leuven
- Clinique CHC Montlégia, Liège
- Institut Jules Bordet, Bruxelles
- CHU UCL St. Luc, Bruxelles
- OLV Aalst, Aalst
- CHU de Liège, site Sart Tilman, Liège
Learn More ->
BGOG-cx-1
Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2 with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma.
Learn More ->
